A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year than the current available oral GLP-1 RA (semaglutide), finds a phase 3 ...
Once-daily orforglipron induced greater reductions in HbA1c and body weight than once-daily oral semaglutide for adults with type 2 diabetes, according to data from the ACHIEVE-3 trial published in ...
Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a ...
“MASLD and T2DM represent intersecting global epidemics with substantial clinical and public health implications,” wrote the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results